The Shingles market report provides current treatment practices, emerging drugs, Shingles market share of the individual therapies, current and forecasted Shingles market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Shingles treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Shingles Overview
Shingles, also known as herpes zoster (HZ), is a viral infection caused by the chickenpox virus, varicella-zoster virus (VZV). Herpes zoster results from activation of the virus, which in many instances has remained latent for years following a primary chickenpox infection. Once active, the virus travels along a nerve to the skin and causes a rash.
Request free sample copy- https://www.delveinsight.com/sample-request/shingles-market
List of regions covered in the report
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
List of Shingles companies involved in the report
- Novartis
- GlaxoSmithKline
- Maruho
- Nobelpharma
- Curevo
- And many others
List of drugs involved in the report
- Famvir (famciclovir)
- Valtrex (valacyclovir)
- Amenalief (amenamevir)
- Shingrix
- Fostoin
- CRV-101
- And many others
Shingles Symptoms
Early symptoms of shingles may include fever and general weakness. During the 2 or 3 days before shingles development, most people have pain, a tingling sensation, or itching in a strip of skin (a dermatome) on one side of the body. Clusters of small, fluid-filled blisters surrounded by a small red area then develop on the strip of skin. Typically, the blisters occur only on the limited area of skin supplied by the infected nerve fibers. They are most common on the torso and face, but they can occur elsewhere as well. In rare cases, the rash appears on the lower body. Though, Shingles may develop at any age but is most common after age 50. The chance of developing shingles increases as people age.
Shingles Treatment Market
Shingrix vaccine has been approved by the US FDA to prevent shingles and is recommended for adults aged 50 years and older. Other than this vaccine, Shingles treatments include several antiviral drugs such as famciclovir or valacyclovir. These drugs do not cure the disease, but they can help relieve shingles symptoms and shorten their duration. Pain–reliving drugs, anti-inflammation drugs, narcotic medications and others are also prescribed for treatment of the symptoms.
Shingles Market Report
Treatment for Shingles must be initiated by a dermatologist or other health-care provider within 3 days of getting the rash. Ideally, if the treatment is initiated within 3 days, it can prevent possible complications, such as long-lasting nerve pain. However, receiving treatment after 3 days still has benefits.
Shingles Market Disease
Antiviral medication and vaccinations are often the most effective shingles treatments, according to the National Foundation for Infectious Diseases. In terms of vaccines, Zostavax and Shingrix are the available for shingles while Famciclovir (Famvir) and valacyclovir (Valtrex) are FDA approved drugs for shingles and acyclovir (Sitavig, Zovirax) is also used sometimes. These drugs do not cure the disease since there is no cure for this indication, but they can help relieve shingles symptoms and shorten their duration. Additionally, pain medicines may help relieve the pain caused by shingles.
Shingles Market Insights
Shingrix is a new shingles vaccine developed by GlaxoSmithKline and was approved by the US FDA in 2017. It contains inactivated varicella-zoster viral particles, which aids the body’s production of more antibodies that are necessary to fight the virus with a stronger immune system response. As an inactive vaccine, it may be administered to patients with compromised immune systems. It reduces the risk of getting shingles by more than 90% and it’s effective for five years.
Two doses are required for Shingrix to be effective. The second dose should be injected within two to six months of the first dose. Both doses are injected into the muscle. It is recommended for patients who are at least 50 years old. Normal side effects include muscle pain, tiredness, fever, and gastrointestinal symptoms.
Shingles Market Report Highlights
- Shingles symptoms are usually less severe in children than in adults.
- Postherpetic neuralgia (PHN) is the most common complication of herpes zoster. PHN is pain that persists in the area where the rash once was for more than 90 days after rash onset, which can last for weeks or months, and occasionally, for years. About 1 in 10 adults with herpes zoster develop PHN.
Request free sample copy- https://www.delveinsight.com/sample-request/shingles-market
Table of content
- Key Insights
- Executive Summary of Shingles
- Competitive Intelligence Analysis for Shingles
- Shingles Market Overview at a Glance
- Shingles: Disease Background and Overview
- Patient Journey
- Shingles Epidemiology and Patient Population
- Unmet Needs
- Key Endpoints of Shingles Treatment
- Marketed Products
- Emerging Therapies
- Shingles: Seven Major Market Analysis
- Attribute analysis
- 7MM: Market Outlook
- Access and Reimbursement Overview of Shingles
- KOL Views
- Shingles Market Drivers
- Shingles Market Barriers
- Appendix
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
Shingles Market Report Methodology
The objective of updating DelveInsight coverage is to ensure that it represents the most up-to-date vision of the industry possible. The DelveInsight is a fully integrated solution for comprehensive intelligence on various pharmaceutical products, both in the market and in the pipeline, across the globe.
Shingles Market Report Highlights
- In the coming years, the Shingles market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
- The companies and academics are working to assess challenges and seek opportunities that could influence Shingles R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- Major players are involved in developing therapies for Shingles. The launch of emerging therapies will significantly impact the Shingles market
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Shingles
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Why should you buy this report?
- The report will help in developing business strategies by understanding trends shaping and driving the Shingles market
- To understand the future market competition in the Shingles market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for Shingles in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for the Shingles market
- To understand the future market competition in the Shingles market
About DelveInsight
DelveInsight is a Business Consultant company and serves as a Knowledge Partner across the value chain of the Pharmaceutical Industry. With the use of proprietary databases and analytical models, DelveInsight provides cutting-edge market and pipeline analysis and API intelligence across all therapy areas to the Pharma and biotech sector, helping clients to quantify market events and evaluate their impact on the valuation of products, portfolios, and companies.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/